Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
about
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertensionSexual function in hypertensive patients receiving treatmentPDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cellsPivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase.Sildenafil reduces insulin-resistance in human endothelial cellsCharacterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgeryTadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinomasGC{alpha}1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handlingSildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow.Tadalafil, a Phosphodiesterase Inhibitor Protects Stem Cells over Longer Period Against Hypoxia/Reoxygenation Injury Through STAT3/PKG-I Signaling.Microvascular alterations after temporary coronary artery occlusion: the no-reflow phenomenon.Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivoPhosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsRole of the NO/cGMP/K(ATP) pathway in the protective effects of sildenafil against ethanol-induced gastric damage in rats.The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction.Does intravenous sildenafil clinically ameliorate pulmonary hypertension during perioperative management of congenital heart diseases in children? - a prospective randomized study.Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.Treatment of pediatric pulmonary hypertensionPhosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway.Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.Phosphodiesterase 5 inhibitors: are they cardioprotective?Drug therapy: Sildenafil for post-operative pulmonary hypertension and Eisenmenger syndrome - A brief review of literature and survey of expert opinion.COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.Preclinical safety evaluation of submicronized sildenafil citrate nebulization solution in small experimental animals.A review of pulmonary arterial hypertension: Part 2: Current and expected treatments.Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats.Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction.Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway.Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease.Perioperative sildenafil therapy for children with ventricular septal defects and associated pulmonary hypertension undergoing corrective surgery: A randomised clinical trial.Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF.Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery.Transplacental sildenafil rescues lung abnormalities in the rabbit model of diaphragmatic hernia.
P2860
Q26852171-2A7D2C2D-F67D-4108-BCE7-64CDEC34031FQ28219420-AABB9751-A8E3-49BB-984C-7635FAB38366Q28262626-AEB25E05-1FF7-4CE0-9271-1A1D8D587D06Q33552229-E244C297-8135-46A6-9FE6-7C417A681AEBQ33569519-6A64FC61-D222-4F3B-B7D3-84DFF3D69F64Q33813006-89533C4B-E346-4002-BF98-AEAF2AD420C0Q34984650-5A373FDD-945D-4127-86F9-3DD53BE52778Q35039558-FB934EEA-BF6B-499D-9EBB-049D2F258380Q35067627-718AC4A0-EF5B-4FED-97C6-94C20F0984AAQ35087054-72D2962C-A623-45C2-AFB9-B1C48AF26BA1Q35545047-97035EEC-D0B0-4F08-B06C-66E3BEC1D71BQ35635261-56CCF295-9ED4-4136-A31E-20AF56F1CD55Q35892175-FD6D8214-B40F-4441-AF1E-7F74C93DB050Q36150572-62AE6BF8-0203-4010-A667-92E7A38D34EEQ36420145-62CFC41F-3842-4552-8F8F-1D2691517AB7Q36460566-83A194B0-D3BB-4EB5-8173-5D3769963539Q36484642-38A8C483-0CF9-4B9B-AFB9-C21B556C02C2Q36500200-C02FB850-8D5D-4CB8-9826-297888F686C4Q36808042-5EAEF8A1-2DFF-4513-840E-DFB8823A40E1Q36939530-FFFC4878-D0CE-47FD-B2F1-F710FF678137Q37012737-0979A146-76D5-42BA-A21B-824C02890422Q37230469-93CADBA0-0DB1-458A-B1C9-9DC1733E133DQ37291307-04DE049D-AD0E-43EA-9984-991B78F1DD82Q37420916-1815600C-6A8A-4D3E-925B-D124313DC0BCQ37497840-2E3E49F9-8F78-464E-96EB-7310F05FBB37Q37714344-66869066-22DA-4735-8F0B-7531D745304AQ38123175-D2AE68C0-6815-4529-8DAD-14095BBC55A0Q38126803-9C43EC13-5426-49FE-91CE-E37D213477EDQ40527687-708C8E72-A918-4E85-82F4-690116487B66Q42340403-A55E9492-A012-43C6-8560-36C5BA030EBAQ42967773-BA61A3BE-9E1B-444D-A428-1E84979A71A7Q43243970-D75B054E-7DFB-484D-B288-203BB720808FQ44907848-BC94B668-2BB5-45F5-83FC-88740FAE4688Q45007647-A8BB211E-7CE3-4895-B0B7-0D9226CB0E78Q45235067-72528006-E355-4690-B777-81D2E8C07E2BQ46431043-D3491256-E296-46E0-92D0-6F2BA4197AC3Q47142011-602E22EE-A90D-4715-B671-F534AE037B34Q48004922-9566C9F3-DAFA-400A-93EC-21E35471F1FEQ48274580-47B606E2-9A0C-4F72-B93D-F1D9009561DAQ51539103-F324823D-D948-45AF-A198-2CCF4127227B
P2860
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
@ast
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
@en
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
@nl
type
label
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
@ast
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
@en
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
@nl
prefLabel
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
@ast
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
@en
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
@nl
P1433
P1476
Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
@en
P2093
Robert A Kloner
Thorsten Reffelmann
P304
P356
10.1161/01.CIR.0000081166.87607.E2
P407
P577
2003-07-01T00:00:00Z